Monuvir200 mg

Monuvir is an oral antiviral medicine used against SARS-CoV-2 (the virus that causes COVID-19).

Established / Authorized Use

• Treatment of mild-to-moderate COVID-19 in adults who have a positive SARS-CoV-2 test result and who are at high risk of progression to severe disease, including hospitalization or death, when authorized alternative treatment options are not accessible or clinically appropriate. Monuvir is authorized for this use under emergency-use style regulatory pathways in a number of jurisdictions (including Bangladesh's DGDA and other regulators), rather than under full standard marketing approval in most countries.
• Treatment should be started as early as possible after symptom onset or a positive test, within the label-specified window (generally within 5 days of symptom onset), since effectiveness is greatest with early initiation.

Not Indicated / Not Authorized

• Monuvir is not authorized for pre-exposure or post-exposure prophylaxis (prevention) of COVID-19.
• Monuvir is not authorized for initiation of treatment in patients hospitalized due to severe or critical COVID-19.
• Monuvir is not a substitute for vaccination against COVID-19.

As part of appropriate antiviral stewardship, Monuvir should be reserved for the authorized at-risk population and should not be used routinely for all COVID-19 cases.

Each capsule contains Molnupiravir 200 mg as the active pharmaceutical ingredient, along with pharmaceutically acceptable excipients.

Monuvir is a synthetic ribonucleoside prodrug that is orally administered and metabolized in the body to an active antiviral nucleoside analog. It works by introducing errors into the genetic material of SARS-CoV-2 during viral replication, reducing the amount of infectious virus.

Monuvir is supplied as an oral capsule for short-course treatment of mild-to-moderate COVID-19 in eligible at-risk adults.

Antiviral agent (COVID-19 specific) - ribonucleoside analog / viral RNA mutagen. Monuvir belongs to this class.

Mechanism

Molnupiravir is a prodrug that is rapidly converted in the body to the active ribonucleoside analog beta-D-N4-hydroxycytidine (NHC). NHC is taken up by cells and phosphorylated intracellularly to form the pharmacologically active ribonucleoside triphosphate (NHC-TP). Viral RNA-dependent RNA polymerase incorporates NHC-TP into viral RNA during replication instead of natural cytidine/uridine, causing an accumulation of errors ("viral error catastrophe" or lethal mutagenesis) in the SARS-CoV-2 genome, which impairs viral replication.

Pharmacokinetics

• Absorption: Orally absorbed, with peak plasma concentration reached within about 1-2 hours; may be taken with or without food.
• Distribution/Metabolism: Rapidly hydrolyzed to NHC in plasma; NHC is not believed to be a clinically relevant substrate, inhibitor, or inducer of major cytochrome P450 (CYP) enzymes or common transporters.
• Elimination half-life: Approximately 7 hours (as NHC).

• Swallow Monuvir capsules whole with a glass of water; do not crush, chew, or open the capsules.
• May be taken with or without food.
• Take doses approximately 12 hours apart, completing the full 5-day course even if symptoms improve.
• Complete the entire prescribed course unless a physician advises otherwise.

Monuvir (via its active metabolite NHC) is not believed to be a clinically significant inhibitor, inducer, or substrate of major cytochrome P450 enzymes, UGT enzymes, or common drug transporters, so its potential for clinically significant drug-drug interactions is considered low.

• No dose adjustment of Monuvir or of commonly co-administered medicines is required based on current data when Monuvir is used for its authorized short 5-day course.
• As with any antiviral, inform the physician or pharmacist of all other medicines being taken, since new interaction data may emerge with continued post-marketing use.

Monuvir is generally well tolerated over its short 5-day course. Reported side effects include:

Common

• Diarrhea
• Nausea
• Dizziness
• Headache

Less Common

• Skin rash or urticaria (hives)
• Mild elevations in liver enzymes

Seek prompt medical advice if severe or persistent symptoms, or signs of an allergic reaction, occur while taking Monuvir.

Pregnancy

Monuvir is not recommended for use during pregnancy. Animal reproduction studies have shown evidence of fetal harm at exposures relevant to the recommended human dose. Monuvir should be used in pregnancy only if a physician determines the potential benefit clearly outweighs the potential risk to the fetus, and only after informed discussion with the patient.

• Individuals who can become pregnant should use a reliable method of contraception during treatment with Monuvir and for 4 days after the last dose.
• Males with partners who can become pregnant should use a reliable method of contraception during treatment with Monuvir and for at least 3 months after the last dose, due to potential effects on developing sperm.

Lactation

It is not known whether Monuvir or its metabolites pass into human breast milk. Because of the potential for adverse effects in a breastfed infant, breastfeeding is not recommended during treatment with Monuvir and for 4 days after the last dose. Consult a physician before breastfeeding during this period.

• Monuvir is authorized only for the specific at-risk adult population and specific timing window described in Indications - it should not be used outside this population as a matter of antiviral stewardship.
• Monuvir is not a substitute for COVID-19 vaccination; patients eligible for vaccination should continue to follow vaccination recommendations.
• Monuvir has not been shown to be effective for pre-exposure or post-exposure prevention of COVID-19 and should not be used for this purpose.
• Monuvir should not be used to initiate treatment in patients hospitalized due to severe COVID-19, since benefit has not been demonstrated in this setting.
• Effectiveness of Monuvir is greatest when started as early as possible after symptom onset or diagnosis; delayed initiation may reduce benefit.
• See Contraindications and Pregnancy and Lactation for population-specific restrictions.

There is limited clinical experience with Monuvir overdose. No specific antidote is available. In case of a suspected overdose of Monuvir, seek immediate medical attention or contact a poison control center or emergency services. Management should be supportive, based on the patient's clinical status, under medical supervision; unsupervised home treatment for a suspected overdose is not recommended.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No dose adjustment of Monuvir is considered necessary in mild-to-moderate renal impairment based on available data; data in severe renal impairment are limited, so use with caution and medical judgment.

Hepatic Impairment

No dose adjustment of Monuvir is considered necessary in mild-to-moderate hepatic impairment based on available data; data in severe hepatic impairment are limited.

Elderly

No dose adjustment of Monuvir is necessary based on age alone; clinical trials included elderly patients with no significant difference in safety or effectiveness observed.

Pediatric

Monuvir is not authorized for patients under 18 years of age (see Pediatric Uses).

Pregnancy and Lactation

See Pregnancy and Lactation section for detailed guidance.

The standard authorized course of Monuvir is 5 consecutive days (800 mg every 12 hours), started as early as possible after symptom onset or a positive COVID-19 test. Treatment should not be extended beyond 5 days.

Ribonucleoside analog antiviral; viral RNA mutagenesis agent. Molnupiravir is the prototype and currently the principal marketed agent in this specific antiviral subclass for COVID-19.

Molnupiravir is a prodrug of the ribonucleoside analog N4-hydroxycytidine (NHC). After oral absorption, Molnupiravir is converted to NHC, which is taken up into cells and phosphorylated to its active triphosphate form (NHC-TP). The viral RNA-dependent RNA polymerase of SARS-CoV-2 mistakenly incorporates NHC-TP into new viral RNA strands in place of natural nucleotides. This introduces an increasing number of mutations into the viral genome with each replication cycle, a process called viral error catastrophe or lethal mutagenesis, which impairs the virus's ability to replicate and reduces infectious viral load.

Monuvir is not authorized for use in patients under 18 years of age. Safety and efficacy of Monuvir have not been established in the pediatric population. This restriction is based on findings in animal studies suggesting Monuvir may affect bone and cartilage growth in a growing skeleton, a theoretical concern that has not been adequately studied in children and adolescents. Alternative, age-appropriate treatment options should be discussed with a pediatrician for children and adolescents with COVID-19.